Acutus Medical, Inc. (NASDAQ:AFIB – Get Rating) was the recipient of a significant decline in short interest during the month of December. As of December 30th, there was short interest totalling 899,000 shares, a decline of 15.2% from the December 15th total of 1,060,000 shares. Based on an average daily volume of 547,500 shares, the short-interest ratio is presently 1.6 days. Approximately 4.7% of the shares of the stock are short sold.
Institutional Investors Weigh In On Acutus Medical
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Acutus Medical by 70.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,142,170 shares of the company's stock valued at $1,005,000 after purchasing an additional 470,719 shares during the period. State Street Corp increased its holdings in shares of Acutus Medical by 11.0% in the 1st quarter. State Street Corp now owns 430,865 shares of the company's stock valued at $599,000 after purchasing an additional 42,578 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Acutus Medical in the 1st quarter valued at about $499,000. AQR Capital Management LLC increased its holdings in Acutus Medical by 844.0% in the second quarter. AQR Capital Management LLC now owns 174,352 shares of the company's stock worth $195,000 after buying an additional 155,883 shares during the last quarter. Finally, Mirabella Financial Services LLP acquired a new position in Acutus Medical in the first quarter worth approximately $48,000. 36.32% of the stock is owned by institutional investors and hedge funds.
Get Acutus Medical alerts:Acutus Medical Stock Up 15.4 %
Shares of NASDAQ:AFIB opened at $1.50 on Friday. Acutus Medical has a 1 year low of $0.48 and a 1 year high of $2.49. The company has a market cap of $42.68 million, a PE ratio of -0.48 and a beta of 0.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.12 and a quick ratio of 4.33. The stock's 50-day moving average is $0.98 and its 200 day moving average is $1.05.
Acutus Medical (NASDAQ:AFIB – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. The business had revenue of $3.64 million for the quarter, compared to analysts' expectations of $3.52 million. Acutus Medical had a negative return on equity of 100.62% and a negative net margin of 545.51%. Sell-side analysts anticipate that Acutus Medical will post -2.84 EPS for the current year.About Acutus Medical
(Get Rating)
Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.
Read More
- Get a free copy of the StockNews.com research report on Acutus Medical (AFIB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.